Controlled bioorthogonal activation of Bromodomain-containing protein 4 degrader by co-delivery of PROTAC and Pd-catalyst for tumor-specific therapy
Journal of Controlled Release · 2024-10 · 374 · 441-453
DOI: 10.1016/j.jconrel.2024.08.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-10. Verfasst von Zhiyao Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medicine/State Key Laboratory of Functions and Applications of Medicinal Plants/Natural Products Research Center of Guizhou Province,…. Hauptthemen laut MEDLINE: Prodrugs, Gold, Neoplasms, Palladium. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
The precise and safe treatment of bioorthogonal prodrug system is hindered by separate administration of prodrug and its activator, which often results in poor therapeutic effects and severe side effects. To address above issues, we herein construct a single bioorthogonal-activated co-delivery system for simultaneous PROTAC prodrug (proPROTAC) delivery and controlled, site-specific activation for tumor-specific treatment. In this co-delivery system (termed AuPLs), prodrug (proPROTAC) and water-soluble Pd-catalyst are first encapsulated by gold nanocubes (AuNCs), which are further coated with a layer of phase-change material (lauric acid/stearic acid, LA/SA). Below 39 °C, the solid state of LA/SA prevents the activation of Pd-mediated bioorthogonal reaction due to the solidification of Pd-catalyst and proPROTAC. Nevertheless, once over 42 °C, the phase change of LA/SA into liquid state, enabled by the photothermal effect of AuNCs, triggers the simultaneous release of proPROTAC and Pd-catalyst and initiates the in situ bioorthogonal reaction for proPROTAC activation. In the tumor-bearing mouse models, the systemic administration of AuPLs results in the accumulation in tumor region, where the photothermal effect activates and controls the tumor-specific bioorthogonal reaction to degrade BRD4 protein, leading to anti-tumor effects with minimized side effects. Overall, the co-delivery proPROTAC and Pd-catalyst and controlled activation by photothermal effects provide a precise way for biorthogonal-based anticancer prodrugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medicine/State Key Laboratory of Functions and Applications of Medicinal Plants/Natural Products Research Center of Guizhou Province, Guizhou Medical University, Guiyang 550025, PR China; College of Phar…
- Guiyang Healthcare Vocational University, Guiyang 550081, PR China.
- School of Basic Medicine/State Key Laboratory of Functions and Applications of Medicinal Plants/Natural Products Research Center of Guizhou Province, Guizhou Medical University, Guiyang 550025, PR China.
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, PR China; School of Pharmacy, Guangdong Medical University, Dongguan 523808, PR China.
- School of Pharmaceutical Sciences, Guizhou University, Guiyang 550025, PR China.
- School of Pharmacy, Guangdong Medical University, Dongguan 523808, PR China.
Zitieren
APA
Li, Z., Jiang, T., Yuan, X., Li, B., Wu, C., Li, Y., Huang, Y., Xie, X., Pan, W., & Ping, Y. (2024). Controlled bioorthogonal activation of Bromodomain-containing protein 4 degrader by co-delivery of PROTAC and Pd-catalyst for tumor-specific therapy. Journal of Controlled Release, 374, 441-453. https://doi.org/10.1016/j.jconrel.2024.08.032
Vancouver
Li Z, Jiang T, Yuan X, Li B, Wu C, Li Y, et al. Controlled bioorthogonal activation of Bromodomain-containing protein 4 degrader by co-delivery of PROTAC and Pd-catalyst for tumor-specific therapy. Journal of Controlled Release. 2024;374:441-453. doi:10.1016/j.jconrel.2024.08.032
BibTeX
@article{Li2024,
author = {Li, Zhiyao and Jiang, Taibai and Yuan, Xu and Li, Bowen and Wu, Chongzhi and Li, Yecheng and Huang, Yong and Xie, Xin and Pan, Weidong and Ping, Yuan},
title = {Controlled bioorthogonal activation of Bromodomain-containing protein 4 degrader by co-delivery of PROTAC and Pd-catalyst for tumor-specific therapy},
journal = {Journal of Controlled Release},
year = {2024},
volume = {374},
pages = {441--453},
doi = {10.1016/j.jconrel.2024.08.032}
}
EUVIMED